Medtronic PLC $MDT Shares Sold by Dodge & Cox

Dodge & Cox cut its position in Medtronic PLC (NYSE:MDT) by 0.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,725,071 shares of the medical technology company’s stock after selling 15,312 shares during the quarter. Dodge & Cox owned 0.60% of Medtronic worth $735,736,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the business. Artisan Partners Limited Partnership grew its holdings in Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after acquiring an additional 31,314 shares in the last quarter. AXQ Capital LP raised its stake in shares of Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after purchasing an additional 54,898 shares during the last quarter. Applied Finance Capital Management LLC acquired a new position in Medtronic in the third quarter worth about $1,308,000. Finally, Willis Investment Counsel increased its holdings in Medtronic by 5.0% in the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after buying an additional 19,192 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Price Performance

NYSE MDT opened at $87.05 on Friday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The firm has a market capitalization of $111.77 billion, a PE ratio of 24.25, a P/E/G ratio of 2.24 and a beta of 0.71. The company’s 50 day simple moving average is $97.96 and its 200 day simple moving average is $96.84. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analysts Set New Price Targets

A number of research firms have commented on MDT. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 target price on shares of Medtronic in a report on Tuesday. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, March 1st. Wells Fargo & Company initiated coverage on Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Sanford C. Bernstein increased their target price on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).